Amundi Grows Holdings in Bath & Body Works, Inc. $BBWI

Amundi increased its position in shares of Bath & Body Works, Inc. (NYSE:BBWI) by 382.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 174,951 shares of the company’s stock after purchasing an additional 138,664 shares during the quarter. Amundi owned approximately 0.08% of Bath & Body Works worth $4,872,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SVB Wealth LLC purchased a new position in Bath & Body Works during the first quarter worth about $35,000. Golden State Wealth Management LLC boosted its holdings in Bath & Body Works by 94.7% during the first quarter. Golden State Wealth Management LLC now owns 1,320 shares of the company’s stock worth $40,000 after purchasing an additional 642 shares during the last quarter. UMB Bank n.a. boosted its holdings in Bath & Body Works by 65.9% during the first quarter. UMB Bank n.a. now owns 1,501 shares of the company’s stock worth $46,000 after purchasing an additional 596 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new position in Bath & Body Works in the first quarter valued at about $69,000. Finally, Brooklyn Investment Group boosted its stake in Bath & Body Works by 394.9% in the first quarter. Brooklyn Investment Group now owns 2,697 shares of the company’s stock valued at $82,000 after acquiring an additional 2,152 shares during the last quarter. 95.14% of the stock is currently owned by hedge funds and other institutional investors.

Bath & Body Works Stock Down 0.2%

NYSE BBWI opened at $28.15 on Thursday. The company’s 50 day moving average is $30.53 and its 200-day moving average is $30.35. Bath & Body Works, Inc. has a 12-month low of $24.94 and a 12-month high of $41.87. The firm has a market cap of $5.81 billion, a P/E ratio of 8.35, a price-to-earnings-growth ratio of 0.97 and a beta of 1.49.

Bath & Body Works (NYSE:BBWI) last posted its quarterly earnings results on Thursday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.37. Bath & Body Works had a net margin of 9.88% and a negative return on equity of 48.43%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the firm posted $0.37 earnings per share. The company’s quarterly revenue was down .8% compared to the same quarter last year. Bath & Body Works has set its Q3 2025 guidance at 0.370-0.45 EPS. FY 2025 guidance at 3.350-3.600 EPS. Equities analysts expect that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 5th. Investors of record on Friday, August 22nd were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Friday, August 22nd. Bath & Body Works’s dividend payout ratio is 23.74%.

Analyst Ratings Changes

A number of research firms have weighed in on BBWI. JPMorgan Chase & Co. boosted their target price on shares of Bath & Body Works from $40.00 to $46.00 and gave the company an “overweight” rating in a research note on Monday, July 28th. Citigroup dropped their target price on shares of Bath & Body Works from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. The Goldman Sachs Group dropped their target price on shares of Bath & Body Works from $44.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday, May 30th. UBS Group dropped their target price on shares of Bath & Body Works from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Friday, August 29th. Finally, Piper Sandler set a $39.00 target price on shares of Bath & Body Works and gave the company an “overweight” rating in a research note on Thursday, May 15th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.62.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.